Swedbank AB Sells 4,700 Shares of Neurocrine Biosciences, Inc. $NBIX

Posted by Stanley Muller on Jul 8th, 2026

Swedbank AB reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 579,429 shares of the company’s stock after selling 4,700 shares during the quarter. Swedbank AB owned approximately 0.58% of Neurocrine Biosciences worth $76,334,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NBIX. USA Financial Formulas acquired a new position in Neurocrine Biosciences during the fourth quarter worth $25,000. DJE Kapital AG acquired a new stake in Neurocrine Biosciences in the 4th quarter valued at $28,000. Geneos Wealth Management Inc. lifted its position in Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares in the last quarter. Meeder Asset Management Inc. lifted its position in Neurocrine Biosciences by 651.6% during the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after buying an additional 202 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $39,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada raised their price objective on Neurocrine Biosciences from $183.00 to $195.00 and gave the company an “outperform” rating in a report on Tuesday. Sanford C. Bernstein assumed coverage on Neurocrine Biosciences in a research report on Friday, May 22nd. They set an “outperform” rating and a $221.00 price target for the company. Needham & Company LLC restated a “buy” rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a research note on Monday, April 6th. Piper Sandler boosted their price target on Neurocrine Biosciences from $190.00 to $207.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, Zacks Research upgraded Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average price target of $188.10.

Check Out Our Latest Stock Report on Neurocrine Biosciences

Neurocrine Biosciences Stock Up 1.9%

Shares of NASDAQ NBIX opened at $177.49 on Wednesday. The business’s 50 day moving average price is $157.87 and its two-hundred day moving average price is $142.16. The company has a market cap of $17.85 billion, a PE ratio of 27.35, a price-to-earnings-growth ratio of 0.69 and a beta of 0.39. Neurocrine Biosciences, Inc. has a twelve month low of $122.14 and a twelve month high of $178.75.

Insider Activity at Neurocrine Biosciences

In related news, insider Jude Onyia sold 11,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $160.25, for a total value of $1,762,750.00. Following the sale, the insider owned 25,846 shares in the company, valued at approximately $4,141,821.50. This represents a 29.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Julie Cooke sold 36,937 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $156.22, for a total value of $5,770,298.14. Following the sale, the insider directly owned 22,374 shares of the company’s stock, valued at $3,495,266.28. This represents a 62.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 365,234 shares of company stock worth $57,031,540 in the last three months. 4.60% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.